Advocacy intelligence hub — real-time data for patient organizations
Lumos Pharma — PHASE3
Lumos Pharma — PHASE3
Changchun GeneScience Pharmaceutical Co., Ltd. — PHASE2
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Shenzhen Kexing Pharmaceutical Co., Ltd. — PHASE2, PHASE3
University Hospital, Angers — NA
Pfizer
VA Office of Research and Development — PHASE3
Cliniques universitaires Saint-Luc- Université Catholique de Louvain — NA
Novo Nordisk A/S
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Anna Aulinas, MD PhD
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Elizabeth A Lawson, MD
Massachusetts General Hospital
Anne Klibanski, MD, MD
Massachusetts General Hospital
📍 BOSTON, MA
Pamela U. Freda, MD, M.D
Columbia University College of Physicians&Surgeons
📍 NEW YORK, NY
Annamaria Colao, MD, PhD
University Federico II of Naples
Deborah P Merke, M.D., M.D
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
📍 BETHESDA, MD